Thursday 21 July 2016

Hemophilia A and B Recombinant Factor Replacement Therapy Market Trends and Forecasts to 2024

Hemophilia A and B Recombinant Factor Replacement Therapy to 2024 is a new market research publication announced by Reportstack. Congenital Hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.
To view the table of contents and know more details please visit Hemophilia A and B Recombinant Factor Replacement Therapy to 2024
The US is the largest global hemophilia market, due to high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. This market growth will be driven by increasing rates of prevalent cases of hemophilia A and B, and increasing uses of recombinant replacement factors in hemophilia A and B patients over the forecast period.
Scope
- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Hemophilia A and B market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B.
- Effectively plan your M&A and partnership strategies by the most promising sales potential

Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

No comments:

Post a Comment